ADOCIA Announces the First Patient Dosed In the BioChaperone^® Lispro Phase III Program with Partner Tonghua Dongbao

Adocia announced the dosing of the first patient with the BioChaperone® Lispro Phase III study. The Phase III program consists of 2 studies treating people with type 1 and type 2 diabetes in 100 clinical centers across China and will enroll a total of c. 1300 patients.